解放军医学院学报Issue(8)：797-800,4.DOI:10.3969/j.issn.2095-5227.2015.08.009
GNP联合化疗治疗难治复发非霍奇金淋巴瘤的疗效分析
Efficacy of GNP combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma
王志红 1孙君重 1杨清明 1周宏伟 1刘默 1曹志刚 1周敏航 1邢丽 1冯少美 1古永建 1彭朝津1
作者信息
- 1. 解放军总医院第一附属医院 老年血液肿瘤科，北京 100048
- 折叠
摘要
Abstract
Objective To observe the efficacy of GNP (gemcitabine, nedaplatin, methyl prednisolone) combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma (NHL).MethodsThe efficacy and adverse responses of 30 patients with refractory and relapse NHL who had voluntarily received GNP chemotherapy in our hospital from January 2009 to July 2013 were retrospectively analyzed. Of the 30 cases, 12 cases were refractory, 13 cases were relapse and 5 cases were progression. 18 cases were B cell lymphoma and 12 cases were T or NK/T cell lymphoma. The median circles of therapy-receiving were 2 circles (2-7 circles). ResultsThe efficacy of GNP combined chemotherapy in treatment for refractory and relapse NHL showed complete remission (CR) in 3 cases, partial remission (PR) in 20 cases, stable disease (SD) in 7 cases. The over response rate (ORR) was 76.7%, and the over survival rate for 1 year reached 86.7%. The progression free survival (PFS) reached 40% with the median PFS of 10 months (95%CI for 5.8- 14.2 months). The adverse responses were slight and the endurement wasfine.ConclusionThere is favorable efficacy for GNP combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma.关键词
吉西他滨/奈达铂/复发难治/非霍奇金淋巴瘤Key words
gemcitabine/nedaplatin/relapse and refracatory/non-hodgkin lymphoma分类
医药卫生引用本文复制引用
王志红,孙君重,杨清明,周宏伟,刘默,曹志刚,周敏航,邢丽,冯少美,古永建,彭朝津..GNP联合化疗治疗难治复发非霍奇金淋巴瘤的疗效分析[J].解放军医学院学报,2015,(8):797-800,4.
